[FOR RELEASE November 5, 2013 China Biologic Reports Financial Results for the Third Quarter and First Nine Months of 2013 --3Q13 Total Sales of $53.2 Million / 9M Total Sales Up 6.6%-- --3Q13 Operating Income Up 13.4% / 9M Operating Income Up 23.0%-- --3Q13 Operating Margin Up 520 bp to 43.6% / 9M Operating Margin Up to 46.3% -- --3Q13] []
[] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [David (Xiaoying) Gao , the Chief Executive Officer of CHINA BIOLOGIC PRODUCTS, INC. (the “Company”), DOES HEREBY CERTIFY that: 1. September 30 , 201 3 2. 5 th day of November , 201 3 . David (Xiaoying) Gao Chief Executive Officer A signed original of this written statement required by Section 906 has been provided to China Biologic Products, Inc.] [Ming Yang , the Chief Financial Officer of CHINA BIOLOGIC PRODUCTS, INC. (the “Company”), DOES HEREBY CERTIFY that: 1. 3 2. 5 th day of November , 201 3 . Ming Yang Ming Yang Chief Financial Officer (Principal Financial Officer) A signed original of this written statement required by Section 906 has been provided to China Biologic Products, Inc. and]
[EXECUTION VERSION CREDIT AGREEMENT Dated as of August 8, 2013 between CHINA BIOLOGIC PRODUCTS, INC. and CHINA MERCHANTS BANK CO., LTD., NEW YORK BRANCH TABLE OF CONTENTS Page No. SECTION 1 Definitions 1 1.1 Definitions 1 1.2 Other Definitional Provisions 8 1.3 Computation of Time Periods 8 1.4 Accounting Terms 8 SECTION 2 THE CREDIT FACILITIES 9 2.1 Term Loan] [STANDBY LETTER OF CREDIT DATE OF ISSUE: August 7, 2013 ADVISING BANK: CHINA MERCHANTS BANK CO., LTD., NEW YORK BRANCH STANDBY LETTER OF CREDIT REF.: 110LG1300050 DATE OF EXPIRY: February 7, 2015 BENEFICIARY (NAME AND ADDRESS): CHINA MERCHANTS BANK CO., LTD., NEW YORK BRANCH, NY DEAR SIRS, AT THE REQUEST OF SHANDONG TAIBANG BIOLOGICAL PRODUCTS CO., LTD. (APPLICANT), WE HEREBY] [Guarantee Agreement Agreement This Guarantee Agreement (hereinafter referred to as this “ 1. Principal Shandong Taibang Biological Products Co., Ltd., as the principal (hereinafter referred to as the “ 2. Guarantor China Merchants Bank Co., Ltd., Beijing Shuangyushu Branch, as the guarantor (hereinafter referred to as the “ [ ] Credit Agreement The Agreement constitutes an integral part of the] []
[EXECUTION VERSION CREDIT AGREEMENT Dated as of August 8, 2013 between CHINA BIOLOGIC PRODUCTS, INC. and CHINA MERCHANTS BANK CO., LTD., NEW YORK BRANCH TABLE OF CONTENTS Page No. SECTION 1 Definitions 1 1.1 Definitions 1 1.2 Other Definitional Provisions 8 1.3 Computation of Time Periods 8 1.4 Accounting Terms 8 SECTION 2 THE CREDIT FACILITIES 9 2.1 Term Loan] [STANDBY LETTER OF CREDIT DATE OF ISSUE: August 7, 2013 ADVISING BANK: CHINA MERCHANTS BANK CO., LTD., NEW YORK BRANCH STANDBY LETTER OF CREDIT REF.: 110LG1300050 DATE OF EXPIRY: February 7, 2015 BENEFICIARY (NAME AND ADDRESS): CHINA MERCHANTS BANK CO., LTD., NEW YORK BRANCH, NY DEAR SIRS, AT THE REQUEST OF SHANDONG TAIBANG BIOLOGICAL PRODUCTS CO., LTD. (APPLICANT), WE HEREBY] [Guarantee Agreement Agreement This Guarantee Agreement (hereinafter referred to as this “ 1. Principal Shandong Taibang Biological Products Co., Ltd., as the principal (hereinafter referred to as the “ 2. Guarantor China Merchants Bank Co., Ltd., Beijing Shuangyushu Branch, as the guarantor (hereinafter referred to as the “ [ ] Credit Agreement The Agreement constitutes an integral part of the] []
[FOR RELEASE August 6, 2013 China Biologic Reports Financial Results for the Second Quarter and First Half of 2013 2Q13 Total Sales Up 6.2% / 1H Total Sales Up 10.2% 2Q13 Operating Margin Up to 47.2% / 1H Operating Margin Up to 47.7% 2Q13 Non-GAAP Net Income Up 30.8% / 1H Non-GAAP Net Income Up 29.9% Agrees to Repurchase 1.48] []
[FOR RELEASE August 6, 2013 China Biologic Reports Financial Results for the Second Quarter and First Half of 2013 2Q13 Total Sales Up 6.2% / 1H Total Sales Up 10.2% 2Q13 Operating Margin Up to 47.2% / 1H Operating Margin Up to 47.7% 2Q13 Non-GAAP Net Income Up 30.8% / 1H Non-GAAP Net Income Up 29.9% Agrees to Repurchase 1.48] []
[] [CHINA BIOLOGIC PRODUCTS, INC. 2008 EQUITY INCENTIVE PLAN RESTRICTED STOCK AWARD AGREEMENT Unless otherwise defined herein, the terms defined in the China Biologic Products, Inc. 2008 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Award Agreement (the “Award Agreement”). I. NOTICE OF RESTRICTED STOCK GRANT You have been granted the right to receive] [CERTIFICATIONS I, David (Xiaoying) Gao, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such] [CERTIFICATIONS I, Ming Yang, certify that: 1. I have reviewed this quarterly report on Form 10-Q of China Biologic Products, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th David (Xiaoying) Gao Chief Executive Officer] [OF THE SARBANES-OXLEY ACT OF 2002 2. Information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company. th Ming Yang Chief Financial Officer (Principal Financial Officer)]
[] [SCHEDULE 13D [Rule 13d-101] (Amendment No. 6)* CHINA BIOLOGIC PRODUCTS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 16938C106 (CUSIP Number) 18th Floor, Jialong International Building, 19 Chaoyang Park Road People's Republic of China (+86) 10-6598-3111 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) August 2, 2013]
[] [SCHEDULE 13D [Rule 13d-101] (Amendment No. 6)* CHINA BIOLOGIC PRODUCTS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.0001 PER SHARE (Title of Class of Securities) 16938C106 (CUSIP Number) 18th Floor, Jialong International Building, 19 Chaoyang Park Road People's Republic of China (+86) 10-6598-3111 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) August 2, 2013]
[EXECUTION VERSION STRICTLY CONFIDENTIAL REDEMPTION AGREEMENT Agreement Company Seller Seller Affiliate Parties Party (Hong Kong ID No. R330968(0), “ This REDEMPTION AGREEMENT (this “ Common Stock WHEREAS, Seller desires to sell to the Company, and the Company desires to redeem and acquire from Seller, an aggregate of 1,479,704 shares of common stock (“ NOW THEREFORE, in consideration of the foregoing] []
